HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $15 to $10.
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $15 to $10.